Vaccine-Elicited Antibody Responses to Influenza A(H3N2) Subclade K
The rapid expansion of H3N2 subclade K represents a major public health concern. This study reports antibody responses to H3N2 subclade K and other influenza strains before and after influenza vaccination.
Adenoviral Inciting Antigen and Somatic Hypermutation in VITT
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector–based vaccination against coronavirus disease 2019.
Anti-neuraminidase and anti-HA stalk antibodies reduce the susceptibility to and infectivity of influenza A/H3N2 virus
Immune responses against neuraminidase (NA) and hemagglutinin (HA) are critical for developing effective influenza vaccines, yet their role in influenza transmission remains unclear.
Effectiveness of long-acting monoclonal antibodies against laboratory-confirmed RSV in children aged 24 months and hospitalised for severe acute respiratory infection, European pilot study, 2024 to 2025
Passive immunisation with long-acting monoclonal antibodies (nirsevimab) targeting the two antigenic subgroups A and B of respiratory syncytial virus (RSV) was authorised by the European Medicines Agency for use in the European Union on 31 October 2022.
Clesrovimab for Prevention of RSV Disease in Healthy Infants
Clesrovimab is a long-acting investigational monoclonal antibody against site IV of the respiratory syncytial virus (RSV) fusion protein.
Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood
It is necessary to increase knowledge about the safety and effectiveness of influenza vaccination during pregnancy to improve awareness among patients and healthcare professionals and increase to increase vaccination coverage.
News
Policy & Recommendations
The European Commission invests in the development of innovative products against respiratory viruses
The technology provides a universal solution to respiratory viruses, regardless of an individual's immune history – for example, people who do not sufficiently respond to a vaccine, or don't get vaccinated
XBB.1.5 monovalent vaccine induces lasting cross-reactive responses to SARS-CoV-2 variants such as HV.1 and JN.1, as well as SARS-CoV-1, but elicits limited XBB.1.5 specific antibodies
The evolution of the antibody response to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is impacted by the nature and number of antigenic exposures.
